Ivosidenib (IVO; AG-120) in IDH1-mutant relapsed or refractory myelodysplastic syndrome: Updated results from a phase 1 study Meeting Abstract
| Authors: | DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Stone, R. M.; Patel, P. A.; Tallman, M. S.; Choe, S.; Wang, H.; Zhang, V.; Dai, D.; Fan, B.; Yen, K. E.; Kapsalis, S. K.; Hickman, D.; Agresta, S. V.; Liu, H.; Wu, B.; Attar, E. C.; Kantarjian, H. M. |
| Abstract Title: | Ivosidenib (IVO; AG-120) in IDH1-mutant relapsed or refractory myelodysplastic syndrome: Updated results from a phase 1 study |
| Meeting Title: | 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019) |
| Keywords: | clinical trial; targeted therapy; myelodysplastic syndromes; mds; mutation analysis; ivosidenib |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 19 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Sep 11-14 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-09-01 |
| Start Page: | S340 |
| Language: | English |
| ACCESSION: | WOS:000483480700373 |
| DOI: | 10.1016/j.clml.2019.07.341 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: MDS-162 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work